Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6

<div>Pooling SVR12 rates of DAA regimens on HCV genotype 6. SVR12, sustained virological response rates at 12 weeks; HCV, hepatitis C virus; DAA, direct-acting antiviral; SOF, sofosbuvir; LDV, ledipasvir; PR, PegIFN + ribavirin.</div>

BioMed Research International

fig2

Figure 2

Figure 2: Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6 